MX2023000693A - Inhibidor de egfr. - Google Patents
Inhibidor de egfr.Info
- Publication number
- MX2023000693A MX2023000693A MX2023000693A MX2023000693A MX2023000693A MX 2023000693 A MX2023000693 A MX 2023000693A MX 2023000693 A MX2023000693 A MX 2023000693A MX 2023000693 A MX2023000693 A MX 2023000693A MX 2023000693 A MX2023000693 A MX 2023000693A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- egfr
- egfr inhibitor
- salt
- general formula
- Prior art date
Links
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 abstract 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 abstract 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229940124597 therapeutic agent Drugs 0.000 abstract 2
- 210000004556 brain Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000035699 permeability Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Abstract
Se proporciona un agente terapéutico para una enfermedad asociada con EGFR, el agente comprende un compuesto que tiene actividad inhibidora de EGFR y tiene propiedades de penetración en el cerebro como un ingrediente activo; la presente invención proporciona un compuesto representado por la fórmula (I) en donde R1, R2, R3, R4 y R5 son como se definen en la presente especificación, o una sal del mismo, y un agente terapéutico para una enfermedad asociada con EGFR, el agente comprende un compuesto representado por la siguiente fórmula (I), o una sal del mismo como un ingrediente activo. (ver Fórmula).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020121525 | 2020-07-15 | ||
| PCT/JP2021/026461 WO2022014639A1 (ja) | 2020-07-15 | 2021-07-14 | Ｅｇｆｒ阻害剤 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023000693A true MX2023000693A (es) | 2023-02-13 |
Family
ID=79554696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023000693A MX2023000693A (es) | 2020-07-15 | 2021-07-14 | Inhibidor de egfr. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230285397A1 (es) |
| EP (1) | EP4197538A1 (es) |
| JP (1) | JPWO2022014639A1 (es) |
| KR (1) | KR20230026451A (es) |
| CN (1) | CN116368136A (es) |
| AU (1) | AU2021309779A1 (es) |
| BR (1) | BR112023000770A2 (es) |
| CA (1) | CA3189460A1 (es) |
| MX (1) | MX2023000693A (es) |
| TW (1) | TW202216152A (es) |
| WO (1) | WO2022014639A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112023000765A2 (pt) | 2020-07-15 | 2023-02-07 | Taiho Pharmaceutical Co Ltd | Cristal de composto de pirimidina |
| US20230255972A1 (en) | 2020-07-15 | 2023-08-17 | Taiho Pharmaceutical Co., Ltd. | Pyrimidine compound-containing combination to be used in tumor treatment |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8426428B2 (en) * | 2008-12-05 | 2013-04-23 | Principia Biopharma, Inc. | EGFR kinase knockdown via electrophilically enhanced inhibitors |
| TW201336847A (zh) * | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| KR102075886B1 (ko) | 2015-09-01 | 2020-02-11 | 다이호야쿠힌고교 가부시키가이샤 | 신규한 피라졸로[3,4-d]피리미딘 화합물 또는 그 염 |
| PT3269370T (pt) | 2016-02-23 | 2020-03-05 | Taiho Pharmaceutical Co Ltd | Novo composto de pirimidina condensada ou sal do mesmo |
| PT3909584T (pt) * | 2019-01-11 | 2024-01-12 | Taiho Pharmaceutical Co Ltd | Composto de pirimidina ou um seu sal |
-
2021
- 2021-07-14 CN CN202180061165.8A patent/CN116368136A/zh active Pending
- 2021-07-14 JP JP2022536419A patent/JPWO2022014639A1/ja active Pending
- 2021-07-14 US US18/016,103 patent/US20230285397A1/en active Pending
- 2021-07-14 MX MX2023000693A patent/MX2023000693A/es unknown
- 2021-07-14 BR BR112023000770A patent/BR112023000770A2/pt unknown
- 2021-07-14 KR KR1020237001973A patent/KR20230026451A/ko active Search and Examination
- 2021-07-14 CA CA3189460A patent/CA3189460A1/en active Pending
- 2021-07-14 TW TW110125853A patent/TW202216152A/zh unknown
- 2021-07-14 WO PCT/JP2021/026461 patent/WO2022014639A1/ja unknown
- 2021-07-14 EP EP21842292.1A patent/EP4197538A1/en active Pending
- 2021-07-14 AU AU2021309779A patent/AU2021309779A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202216152A (zh) | 2022-05-01 |
| KR20230026451A (ko) | 2023-02-24 |
| BR112023000770A2 (pt) | 2023-02-07 |
| CA3189460A1 (en) | 2022-01-20 |
| US20230285397A1 (en) | 2023-09-14 |
| JPWO2022014639A1 (es) | 2022-01-20 |
| AU2021309779A1 (en) | 2023-02-23 |
| CN116368136A (zh) | 2023-06-30 |
| EP4197538A1 (en) | 2023-06-21 |
| WO2022014639A1 (ja) | 2022-01-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MY140638A (en) | New heterocyclic compounds, which are active as inhibitors of beta-lactamases | |
| NO20073743L (no) | Forbindelser med Kv4 ionekanal aktivitet | |
| AU2009258496A8 (en) | Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity | |
| NO20090581L (no) | Hydroksylerte og metoksylerte syklopenta[D]pyrimidiner som AKT-proteinkinaseinhibitorer | |
| BRPI0412347A (pt) | 2-aminofenil-4-fenilpiridinas como inibidores de quinase | |
| NO20070557L (no) | Ftalazinderivater som PARP-inhibitorer | |
| MX2023000693A (es) | Inhibidor de egfr. | |
| GB0112348D0 (en) | Compounds | |
| MX2021011606A (es) | Compuestos dirigidos a prmt5. | |
| AU2020288567A8 (en) | Pyrrolopyrimidine compound and use thereof | |
| MXPA05010440A (es) | Amidas del acido isoquinolina-5-sulfonico como inhibidores de la akt (proteina quinasa b). | |
| PH12019500394A1 (en) | Bicyclic nitrogenated heterocyclic compound | |
| CA3156303A1 (en) | 5-FLUORONICOTINAMIDE DERIVATIVES AND THEIR USES | |
| MX2021012105A (es) | Compuestos de pirrol. | |
| ZA202204666B (en) | 2-isoindol-1,3,4-oxadiazole derivatives useful as hdac6 inhibitors | |
| MX2022006333A (es) | Compuesto triheterociclico como inhibidor de jak y uso del mismo. | |
| DE602005017162D1 (de) | 3-arylthioindol-2-carbonsäureamidderivate und ihre analoge als hemmer von caseinkinase i | |
| PH12020551624A1 (en) | Pyrazole compounds substituted with heteroaryl and pharmaceutical use thereof | |
| PH12020552186A1 (en) | Cyanotriazole compounds and uses thereof | |
| MX2021008632A (es) | Moléculas cíclicas como inhibidores de la tirosina cinasa de bruton. | |
| ZA202303913B (en) | Pyrimidine carboxamide compound and application thereof | |
| WO2023141432A3 (en) | Apol1 inhibitors and methods of use | |
| RS115804A (en) | Pyrrolidine derivatives as oxytocin antagonists | |
| UA91549C2 (ru) | Производные хинолина как антибактериальные агенты | |
| MX2022013692A (es) | Compuesto que tiene actividad inhibidora de desmetilasa 5 (kdm5) y uso farmaceutico del mismo. |